Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for unresectable colorectal peritoneal metastases
2024-517152-34-00Phase 2Authorised
- Sponsor
- Catharina Ziekenhuis
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan in colorectal cancer (CRC), sponsored by Catharina Ziekenhuis. Primary endpoints: Overall survival from diagnosis of peritoneal metastases and Overall survival from start of first treatment cycle. Planned start Sep 2024; status: authorised.
02
Drugs
irinotecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2024-517152-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517152-34-00.